NCT02743832 A Study on Tumor Budding Guiding Individualized Surgical Planning of Early-stage Oral Squamous Cell Carcinoma.
| NCT ID | NCT02743832 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Jinsong Hou |
| Condition | Carcinoma, Squamous Cell |
| Study Type | INTERVENTIONAL |
| Enrollment | 524 participants |
| Start Date | 2026-05-04 |
| Primary Completion | 2026-05-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 524 participants in total. It began in 2026-05-04 with a primary completion date of 2026-05-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to determine whether cervical lymph node dissection is necessarily performed in the presence of early-stage oral squamous cell carcinoma.
Eligibility Criteria
Inclusion Criteria: 1. Han race; 2. Oral squamous cell carcinoma is confirmed by pathology; 3. The section of oral squamous cell carcinoma including primary two-thirds prior to the tongue, buccal mucosa， gingiva， mouth floor， hard palate mucosa; 4. The primary lesion is no more than 4cm; 5. Do not find cervical lymph node metastases and distant metastasis in the clinical examination including physical examination and MRI; 6. Patients and families agree to participate in the study; 7. Patients do not have cognitive disorders. Exclusion Criteria: 1. Do not meet the inclusion criteria; 2. The primary lesion is more than 4cm or invade adjacent tissues; 3. Do not review on schedule; 4. Patients receive not only surgical procedures, but other antineoplastic treatment; 5. There are serious adverse events after operation; 6. Patients quit the study voluntarily; 7. Patients quit the study because of physical condition.
Contact & Investigator
Jinsong Hou, PhD
STUDY DIRECTOR
Guanghua School of Stomatology, Hospital of Stomatolagy Sun Yat-sen University
Frequently Asked Questions
Who can join the NCT02743832 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, up to 70 Years, studying Carcinoma, Squamous Cell. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02743832 currently recruiting?
Yes, NCT02743832 is actively recruiting participants. Contact the research team at houjsgz@aliyun.com for enrollment information.
Where is the NCT02743832 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT02743832 clinical trial?
NCT02743832 is sponsored by Jinsong Hou. The principal investigator is Jinsong Hou, PhD at Guanghua School of Stomatology, Hospital of Stomatolagy Sun Yat-sen University. The trial plans to enroll 524 participants.